EU drug regulator gives green light to Pfizer COVID pill for high-risk patients - SABC News - Breaking news, special reports, world, business, sport coverage of all South African current events. Africa's news leader.

The European Union's drug regulator on Thursday gave the green light to Pfizer Inc's antiviral COVID-19 pill for treating adults at risk of severe illness, as the region scrambles to boost its arsenal to fight the Omicron variant.

2022-01-28 04:46:00 AM

The European Union’s drug regulator on Thursday gave the green light to Pfizer Inc’s antiviral COVID-19 pill for treating adults at risk of severe illness, as the region scrambles to boost its arsenal to fight the Omicron variant.

The European Union's drug regulator on Thursday gave the green light to Pfizer Inc's antiviral COVID-19 pill for treating adults at risk of severe illness, as the region scrambles to boost its arsenal to fight the Omicron variant.

Image: ReutersThese oral drugs, especially Pfizer's, are seen as promising new treatment options that can be taken at home at the onset of COVID-19 symptoms to help prevent hospitalisations and deaths.The European Union’s drug regulator on Thursday gave the green light to Pfizer Inc’s antiviral COVID-19 pill for treating adults at risk of severe illness, as the region scrambles to boost its arsenal to fight the Omicron variant.

The endorsement by the European Medicines Agency (EMA) for a conditional approval, if followed as usual by the European Commission, allows EU member states to deploy the drug after the regulator gave guidance for its emergency use late last year.Italy, Germany and Belgium are among a handful of EU countries that have bought the drug, branded as Paxlovid.

Read more: SABC News »

And when it mutates again do tou need another? When will be the final injection?

Covid-19 supplies stolen at Western Cape schools over the holidaysThe Western Cape education department recorded 41 burglary and vandalism incidents at schools during the December holidays.

SA reports 160 deaths and 4‚100 new Covid-19 cases in 24 hoursNICD says higher death toll linked to clearing backlog of mortality cases

England revives Plan A in bid to live alongside Covid-19Mask mandates and pandemic passes are no longer required

COVID-19: ‘End the National State of Disaster,’ experts sayCOVID-19: ‘End the National State of Disaster,’ experts say The National State of Disaster has been in place since March 2020 and is expected to continue at least until 15 February 2022

Austria to end lockdown for Covid unvaccinatedAustria to end lockdown for Covid unvaccinated Austria on Wednesday announced it was ending a lockdown for those unvaccinated as it prepares to become the first EU country to make Covid-19 jabs mandatory from next week.

COVID-19 in SA | Infections increase by 3,197South Africa recorded 3,197 new COVID-19 infections in the past 24 hours. Find a new headline, nobody cares anymore! Who cares? Qhubeka ubasabise khona bezojova 😂😂😂😂

@SABCNews Image: Reuters These oral drugs, especially Pfizer's, are seen as promising new treatment options that can be taken at home at the onset of COVID-19 symptoms to help prevent hospitalisations and deaths. The European Union’s drug regulator on Thursday gave the green light to Pfizer Inc’s antiviral COVID-19 pill for treating adults at risk of severe illness, as the region scrambles to boost its arsenal to fight the Omicron variant. The endorsement by the European Medicines Agency (EMA) for a conditional approval, if followed as usual by the European Commission, allows EU member states to deploy the drug after the regulator gave guidance for its emergency use late last year. Italy, Germany and Belgium are among a handful of EU countries that have bought the drug, branded as Paxlovid. The United States in December authorised Paxlovid and Merck’s similar drug molnupiravir. EU health commissioner Stella Kyriakides said the bloc was now making good progress on lining up treatments, which she described as a second line of defence after vaccines. Merck’s pill is also under review in the EU, but is taking longer to approve because the company revised its trial data in November, saying the drug was significantly less effective than previously thought. These oral drugs, especially Pfizer’s, are seen as promising new treatment options that can be taken at home at the onset of COVID-19 symptoms to help prevent hospitalisations and deaths. Paxlovid, a two-drug antiviral regimen, was nearly 90% effective in preventing hospitalisations and deaths in patients at high risk of severe illness, according to data from the company’s clinical trial. Recent lab data suggests the drug retained its effectiveness against the Omicron variant as well. In the trial however, it was only tested on unvaccinated individuals, raising questions on its potential use in high-risk patients who did get inoculated. EMA did not limit its endorsement to the non-vaccinated. Germany ordered 1 million courses late in December. Health Minister Karl Lauterbach said on January 2 he expected the country’s drug regulator to give a national emergency go-ahead before the end of the month and that rollout would start then. Italy will receive 200 000 courses in February and has the option to buy an additional 400 000. This entry was posted on 28 Jan 2022,03:44AM at 3:44 AM and is filed under